Shares in British biopharmaceutical firm Mereo Biopharma ($MREO) saw a wipeout of over 90% on Monday after two of its ...

Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) tumbled 43.7% to $19.26 in pre-market trading after the company and its partner ...

Investing.com -- Mereo BioPharma Group plc (NASDAQ:MREO) stock plunged 90.3% on Monday after the company announced that its Phase 3 clinical trials for setrusumab in Osteogenesis Imperfecta failed to ...

The Dow Jones Industrial Average and other major indexes fell Monday afternoon as investors sold holdings in this ...

Shares of Ultragenyx and Mereo BioPharma were rocked by disappointing late-stage trial results of their brittle-bone disease treatment. It's looking like a poor end to 2025 for investors in two ...

ArriVent BioPharma is rated a Strong Buy, driven by Firmonertinib’s clinical progress and de-risking. Click here to read my ...

Ultragenyx Pharmaceutical and Mereo BioPharma said their two Phase 3 trials for setrusumab to treat rare bone disorder osteogenesis imperfecta, didn't meet their main goal of reducing fracture rates.

The biotechnology firm, which develops small-molecule drugs for oncological and inflammatory diseases, revealed plans for a 1-for-3,000 reverse split of its ordinary shares. The move comes after ...

On December 16, Julian Emanuel, Senior Managing Director at Evercore ISI, shared his outlook on the equity market and the ...

As of Monday, December 29, Praxis Precision Medicines, Inc.’s PRAX share price has surged by 15.27%, which has investors ...

Veeva Systems Inc. is downgraded to Hold with reduced price target of $236, reflecting limited upside from current levels.

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...